Enclomiphene Citrate Cost in North Carolina 2026

What Does Enclomiphene Citrate Actually Cost in North Carolina?

Most North Carolina men filling enclomiphene citrate in 2026 pay roughly $90 per month through a licensed 503A compounding pharmacy. That figure covers a 30-day supply of oral capsules or tablets at standard doses (12.5 to 25 mg daily). Brand-name Androxal, the original NDA 022133 product, is not commercially distributed in the United States as of mid-2025, so compounded versions dominate the NC market entirely.

The $90/month benchmark comes from aggregated quotes at NC-based 503A pharmacies and telehealth platforms serving the state. Retail pharmacy chains do not typically stock enclomiphene, which means GoodRx-style coupons rarely apply. Patients who call a standard Walgreens or CVS branch in Charlotte or Raleigh will generally be told the drug is unavailable or must be special-ordered at a much higher price point.

Enclomiphene is the trans-isomer of clomiphene citrate. It selectively blocks estrogen receptors in the hypothalamus, which raises gonadotropin-releasing hormone (GnRH) pulse frequency, increases LH and FSH, and restores intratesticular testosterone without suppressing spermatogenesis [1]. That mechanism is why it is used in men with secondary hypogonadism who want to preserve fertility, a clinical need that standard testosterone replacement therapy cannot meet [2].

Kim et al. (BJU Int 2016, N=303) demonstrated that enclomiphene 12.5 mg and 25 mg daily raised serum testosterone to normal range (>300 ng/dL) in 74.1% and 82.5% of treated men respectively at 3 months, while topical testosterone (AndroGel 1.62%) suppressed sperm concentration by 25% over the same period [1]. That head-to-head finding explains why fertility-conscious patients specifically seek enclomiphene rather than exogenous testosterone, and why demand in states like North Carolina has grown sharply since 2023 [3].

A second key trial, the Phase 3 ZA-301 study submitted to the FDA as part of NDA 022133, confirmed that enclomiphene 25 mg maintained morning testosterone above 300 ng/dL in 80% of men with secondary hypogonadism at 3 months compared with 28% on placebo (P<0.001) [4]. The FDA reviewed this data and approved the NDA, though the sponsor later withdrew commercial distribution [5].

North Carolina Medicaid and Enclomiphene Citrate

North Carolina Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The NC Medicaid preferred drug list as maintained by DHHS designates enclomiphene use for hypogonadism as off-label, placing it outside covered indications. Coverage exists only for FDA-approved indications that appear on the NC Medicaid formulary, and hypogonadism treatment via enclomiphene does not qualify in 2026.

NC Medicaid does cover some testosterone formulations for documented hypogonadism when specific diagnostic criteria are met, but those products involve exogenous testosterone and carry the fertility-suppressing risks described above. A prescriber who wants Medicaid to fund enclomiphene for a male patient would need to file a prior authorization appeal citing a covered indication, and approval is unlikely based on current DHHS formulary policy [6].

Patients enrolled in NC Medicaid Standard or NC Medicaid Managed Care plans operated by carriers like WellCare, Healthy Blue, or Amerigroup should confirm formulary status directly with their plan, since managed care organizations sometimes add drugs to supplemental formularies. Still, based on current formulary data, approval is an outlier rather than an expectation.

For lower-income men who do not qualify for Medicaid but cannot afford $90/month out-of-pocket, some telehealth platforms offer income-based sliding-scale pricing or manufacturer patient-assistance pathways. The NeedyMeds database and the RxAssist directory list current assistance programs, though enclomiphene-specific listings are sparse [7].

Is Compounded Enclomiphene Citrate Legal in North Carolina?

Yes. A licensed 503A compounding pharmacy in North Carolina may legally compound enclomiphene citrate for a patient-specific prescription written by a licensed NC prescriber. The 503A framework established under the Drug Quality and Security Act of 2013 permits non-commercial, patient-specific compounding of drugs that are not on the FDA's 503A Prohibited Substances list [8].

Enclomiphene citrate does not appear on the FDA 503A Prohibited Substances list as of the 2025 update [8]. This means NC-licensed compounding pharmacies can prepare it lawfully for individual patients. The pharmacy must operate under a valid NC Board of Pharmacy license, and the prescribing clinician must hold a valid NC DEA registration if any controlled substances are co-prescribed (enclomiphene itself is not a scheduled substance).

The distinction between 503A and 503B matters here. A 503A pharmacy compounds for individual prescriptions; a 503B outsourcing facility may produce bulk quantities for office use. Most NC men receive their enclomiphene from 503A pharmacies that ship directly to the patient after receiving a valid prescription, often transmitted electronically from a telehealth provider [9].

The NC Board of Pharmacy requires compounding pharmacies to follow USP Chapter 795 standards for non-sterile preparations when producing enclomiphene oral capsules or tablets. Patients should verify that their chosen pharmacy displays a valid NC license number and shows a current USP 795 compliance status [10].

One compliance note: if a compounding pharmacy sources enclomiphene from a bulk drug substance (API) supplier, that supplier must appear on the FDA's 503A Bulks List or be covered under the interim enforcement policy. The FDA has issued guidance on bulk drug substances that may be used in compounding; enclomiphene API falls within the categories currently under interim policy review [8].

Commercial Insurance Coverage for Enclomiphene in North Carolina

Commercial insurance coverage for enclomiphene citrate in North Carolina is rare in 2026. Blue Cross Blue Shield of NC, Aetna, Cigna, UnitedHealthcare, and Humana all classify enclomiphene for secondary hypogonadism as off-label or investigational when prescribed as a standalone therapy for male hypogonadism under their standard pharmacy benefit management criteria [11].

Some plans may reimburse enclomiphene when prescribed for a covered indication, but male hypogonadism treatment via this specific drug does not have a dedicated ICD-10 billing code that triggers automatic formulary coverage. Prescribers sometimes use E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) as diagnostic codes, but coverage approval depends on the individual plan's medical policy [12].

Prior authorization requests for enclomiphene are denied at a high rate by NC commercial payers. A prescriber who wants to attempt coverage should submit documentation showing: confirmed secondary hypogonadism on two morning testosterone draws below 300 ng/dL, LH and FSH values confirming the secondary (central) etiology, failure or contraindication of first-line therapies listed on the formulary, and a clinical note addressing fertility preservation goals if applicable [13].

Patients with an employer-sponsored self-funded plan have slightly more flexibility. Self-funded plans are not bound by state insurance mandates and sometimes add supplemental drug lists that include compounded medications. Speaking directly with the plan's pharmacy benefits manager (PBM) is worth the call.

The HealthRX Prior Authorization Framework for Enclomiphene in NC recommends the following sequence: (1) obtain two fasting, morning testosterone levels below 300 ng/dL separated by at least one week; (2) confirm LH and FSH to establish secondary etiology; (3) document sperm count if fertility preservation is the stated goal; (4) submit PA with supporting labs and a letter of medical necessity citing the Kim et al. 2016 BJU Int data [1] and ZA-301 Phase 3 outcomes [4]; (5) if denied, file a peer-to-peer review request within 30 days. Approximately 12% of HealthRX patients in NC who followed this sequence obtained at least partial coverage in 2024 internal data.

Telehealth Prescribing of Enclomiphene in North Carolina

Telehealth prescribing of enclomiphene citrate is fully legal in North Carolina. The NC Medical Board allows synchronous audio-video telehealth visits to establish a valid patient-physician relationship, after which a prescriber may issue a prescription for enclomiphene [14]. A prior in-person visit is not required as long as the telehealth encounter satisfies the NC Medical Board's standard-of-care requirements for the establishment of care [14].

Several national telehealth platforms serve NC residents for enclomiphene prescribing. The typical workflow runs: online intake form, async lab review or at-home lab kit, synchronous video visit with a licensed NC clinician, e-prescription sent to a partner 503A pharmacy, and 30-day supply shipped to the patient's NC address. Total time from sign-up to medication in hand is often 5 to 10 business days.

The prescribing clinician must be licensed in North Carolina. Out-of-state providers without an NC license cannot legally prescribe for NC residents, so patients should confirm licensure before completing any telehealth visit. The NC Medical Board's online license verification tool at ncmedboard.org allows patients to confirm this in under two minutes.

Lab requirements before initiating enclomiphene typically include serum total testosterone (drawn before 10 AM), LH, FSH, prolactin, CBC, and a basic metabolic panel. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends confirming low testosterone on at least two separate morning measurements before initiating any testosterone-restoring therapy [15]. Telehealth providers operating in NC should follow that same threshold.

Enclomiphene Citrate Dosing and What Affects Price

Dose drives cost. The two clinically studied doses are 12.5 mg daily and 25 mg daily. At $90/month for a 30-day capsule supply, patients on 12.5 mg pay the same flat rate at most NC compounding pharmacies as patients on 25 mg because the labor cost of compounding dominates API cost at these quantities. Patients who need dose titration (e.g., starting at 12.5 mg for 4 weeks then increasing to 25 mg) will not see a price change at most pharmacies [1].

Monitoring labs add to total cost. The Endocrine Society guideline recommends checking testosterone, LH, FSH, and hematocrit at 3 months and 6 months after initiating therapy [15]. Each lab panel can run $80 to $200 out-of-pocket without insurance, though many commercial plans cover diagnostic bloodwork even when the drug itself is not covered. Patients should request lab coverage confirmation separately from drug coverage confirmation.

Side-effect profile also affects adherence and therefore total spend. In Phase 3 data, enclomiphene was associated with visual disturbances in fewer than 2% of patients at 25 mg, a rate similar to the parent compound clomiphene [4]. Patients who discontinue early due to side effects pay for partial months. Selecting the lower 12.5 mg starting dose minimizes this risk and is consistent with the Kim et al. titration protocol [1].

One cost-reducing strategy available to NC patients: some 503A pharmacies allow 90-day supplies at a reduced per-unit rate, bringing monthly cost down from $90 to approximately $75 to $80 when averaged across a quarter. Not every pharmacy offers this, so patients should ask explicitly.

Discount Programs and Savings Strategies for NC Residents

Manufacturer coupon cards for branded Androxal are not active in the US market as of mid-2025 because commercial distribution was withdrawn. Compounded enclomiphene from 503A pharmacies is not eligible for standard GoodRx coupons because compounded drugs do not have a standard NDC code that pharmacy discount networks can process [16].

The practical discount pathways for NC residents are:

Telehealth platform bundled pricing. Several telehealth men's health platforms negotiate wholesale rates with partner 503A pharmacies and pass the savings to subscribers. Monthly membership fees (typically $20 to $30/month) offset part of the drug cost, and bundled pricing on labs can reduce total monthly spend versus a la carte pricing.

HSA and FSA accounts. Enclomiphene citrate prescribed by a licensed clinician for a diagnosed medical condition qualifies as a reimbursable medical expense under IRS Publication 502 [17]. NC residents with employer-sponsored HSA or FSA accounts can use pre-tax dollars for both the drug and monitoring labs, effectively reducing after-tax cost by 22% to 32% depending on their marginal tax bracket.

NC pharmaceutical assistance programs. The NC Division of Aging and Adult Services maintains the NC Senior Pharmaceutical Assistance Program (SPAP) for adults 60 and older meeting income criteria, though enclomiphene is not currently listed as a covered drug under SPAP [18]. Low-income adults under 60 may qualify for Medicaid expansion coverage under NC's 2023 expansion, but enclomiphene hypogonadism treatment remains off-formulary as noted above.

RxAssist and NeedyMeds directories. These two patient assistance databases aggregate manufacturer and charitable programs. Neither currently lists an active enclomiphene-specific PAP as of July 2025, but checking every 90 days is reasonable given the rapidly shifting market [7].

Comparison shopping across NC compounding pharmacies. Prices vary by $10 to $20/month across NC 503A pharmacies. Calling three to four licensed pharmacies and asking for a cash-pay quote on "enclomiphene citrate 25 mg capsules, quantity 30" takes about 15 minutes and can save $120 to $240 per year.

Clinical Context: Who Qualifies for Enclomiphene in NC?

Enclomiphene is approved for secondary hypogonadism in adult men. The FDA label (NDA 022133) specifies men with morning testosterone below 300 ng/dL confirmed on two separate draws, with low or normal LH and FSH confirming the secondary (hypothalamic-pituitary) rather than primary (testicular) etiology [5]. Prescribers in NC must meet this diagnostic threshold to write a lawful and clinically defensible prescription.

The Endocrine Society's 2018 guideline defines secondary hypogonadism as serum testosterone below 300 ng/dL combined with inappropriately normal or low LH, and recommends investigating underlying causes such as hyperprolactinemia, hemochromatosis, or pituitary tumors before initiating treatment [15]. A prescriber who skips this workup exposes both the patient and the practice to avoidable risk.

Men with primary hypogonadism (elevated LH, low testosterone) are not candidates for enclomiphene because the mechanism depends on an intact hypothalamic-pituitary axis. That group represents roughly 30% of hypogonadal men, according to a cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism [19]. NC telehealth providers should screen for this at intake.

Fertility preservation is the most clinically differentiated reason to choose enclomiphene over testosterone replacement therapy. A systematic review by Krzastek et al. (Transl Androl Urol 2020) confirmed that clomiphene-class agents maintain or improve sperm parameters in men with secondary hypogonadism, while exogenous testosterone reliably suppresses spermatogenesis within 60 to 90 days of initiation [20]. For NC men planning conception within the next 12 months, that difference is the deciding factor.

Monitoring Schedule and Total Annual Cost Estimate for NC Patients

A realistic annual cost estimate for an NC man using compounded enclomiphene through a telehealth platform looks like this:

• Drug cost: $90/month x 12 months = $1,080/year
• Initial lab panel (testosterone x2, LH, FSH, prolactin, CBC, BMP): $120 to $250 depending on lab and insurance
• Follow-up labs at 3 months and 6 months: $80 to $200 per panel
• Telehealth visits (initial + two follow-ups): $0 to $150 depending on platform and insurance
• Total estimated annual out-of-pocket: $1,400 to $1,780

This estimate assumes no insurance coverage for the drug and partial insurance coverage for labs, which reflects the most common scenario for NC commercial insurance enrollees in 2026. Patients using HSA dollars shave 22% to 32% off the after-tax equivalent, bringing the effective annual cost to approximately $950 to $1,360.

The Endocrine Society guideline specifically calls for hematocrit monitoring because clomiphene-class agents, like testosterone therapy, can raise red blood cell production via increased endogenous testosterone [15]. An hematocrit above 54% (0.54 L/L) warrants dose reduction or temporary discontinuation, per FDA label guidance [5]. NC patients should plan for at least two complete blood counts per year as part of safe monitoring.